BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CND319 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CND319\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07712939-6323@assetmemo.bio
DTSTAMP:20261121T005414Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:CND319: Phase 1 readout est. (NCT07712939)
DESCRIPTION:CND319\, phase 1\, Rheumatoid Arthritis.\nStudy: A Phase 1\, Fi
 rst-in-Human Study of CND319 in Healthy Participants and Patients With Rhe
 umatic Diseases\nEstimated primary completion: 31 March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cnd319#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07712939
URL:https://assetmemo.bio/drug/cnd319#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
